Co-Diagnostics Completes Analysis of Updated 2-Gene MPOX RUO Test

Brief Summary

Co-Diagnostics, Inc. completed an analysis update for its 2-gene MPOX RUO test, confirming its full reactivity to the prevalent 1B class of MPOX strains over the past year .

Impact of The News

Economic and Financial Domain Level:

• Level: Product Level

Introduction to the Event:

Co-Diagnostics, Inc. has successfully finalized an analysis update for its 2-gene MPOX RUO test, which assures complete reactivity to MPOX strains, including the 1B class that has been prevalent in the past year. This development is significant as it reinforces the test’s relevance and effectiveness in detecting these specific strains .

Impact Transmission Path:

• Company Impact: The event primarily impacts Co-Diagnostics, Inc. by potentially enhancing its product’s credibility and marketability. The successful update can lead to increased demand in the research and diagnostic markets, thereby potentially boosting the company’s revenue and market share.
• Industry Impact: In the broader diagnostic industry, this development may push competitors to ensure their tests are equally responsive to these strains, possibly leading to increased research and development efforts and a competitive race to capture market share.

Overall, this event at the product level can positively influence Co-Diagnostics, Inc.'s positioning in the diagnostic industry, potentially impacting its financial performance and competitive stance.